Get the SPI Wire

AIM ImmunoTech Inc.

NASDAQ:ORGO
Annual Meeting

of Shareholders

MEETING DATE

07/15/2026
DEF 14A FILED
06/25/2026
PUBLISHED
06/25/2026 12:55 pm
TIME TO PUBLISH
06/27/2026
METHODOLOGY
approve
EXCHANGE NASDAQ:ORGO · CUSIP

RECONCILED · MIXED

Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.

7
FOR
0
AGAINST
0
WITHHOLD
7
BALLOT ITEMS

ITEM-BY-ITEM RECOMMENDATIONS

1
Approve issuance of more than 19.99% of common stock upon exercise of Class H warrants
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states approval conditions additional gross proceeds and the company may need capital to continue operations.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
2
Approve issuance of more than 19.99% of common stock upon exercise of Class I warrants
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states approval conditions additional gross proceeds and the company may need capital to continue operations.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
3
Approve issuance of more than 19.99% of common stock upon exercise of Class J warrants
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states approval conditions additional gross proceeds and the company may need capital to continue operations.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
4
Approve issuance of more than 19.99% of common stock upon conversion or other satisfaction of the February 16, 2024 promissory note
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states approval may avoid cash repayment and the company may need capital to continue operations.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
5
Approve issuance of more than 19.99% of common stock upon conversion or other satisfaction of the November 18, 2025 promissory note
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states approval may avoid cash repayment and the company may need capital to continue operations.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
6
Approve alternate certificate amendments for a reverse stock split up to 1-for-25
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states the proposal could avoid delisting if the stock price drops to $0.10 per share.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
7
Approve adjournment of the special meeting if necessary
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states adjournment would permit further solicitation of proxies if needed.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.

Ledger

3572b424982318c6fec27ae230b9bb4f773d6cbe287509dffb0e3e03948acfe1

Search company, ticker, executive, director or issue

    The SPI Wire · Proxy Intelligence

    Get every ballot call, before the vote.

    FOR, AGAINST or WITHHOLD on each covered ballot item — published within 48 hours of the definitive proxy filing. Follow the companies you own, or take the full feed.




    Pick the companies you own — you’ll only hear from us on their ballots.

    The SPI Wire covers proxy ballots only — it has nothing to do with Signal Research investigations. Research and analysis for informational purposes; not legal, investment, or voting advice. Unsubscribe anytime.

    Submit Information








      Join Monitoring List




        Receive Research Updates